Our offices will be closed from 23rd December 2024 to 3rd January 2025 for a two-week holiday break. Regular operations will resume on 6th January 2025, and we will follow up on any pending matters at that time. Wishing you a wonderful holiday season!
The multiplex digital PCR company, Stilla Technologies makes absolute quantification of multiple genetic markers and multiple tests from a single sample possible for the first time.
About Stilla Technologies
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing.
Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA.
